Chiara Pisano

Dr. Chiara Pisano


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAlessandro Samuelly
Alessandro Samuelly
RSRosario Francesco Di Stefano
Rosario Francesco Di Stefano
FTFabio Turco
Fabio Turco
MDMarco Donatello Delcuratolo
Marco Donatello Delcuratolo
CPChiara Pisano
Chiara Pisano
CBConsuelo Buttigliero
Consuelo Buttigliero
The use of immune checkpoint inhibitors (ICIs) in combination with tyrosine kinase inhibitors or other ICIs has significantly improved the prognosis for patients with mccRCC. This marks a major milestone in the treatment of mccRCC. Nonetheless, most patients will discontinue first-line therapy. In this narrative review, we analyze the different patterns of treatment discontinuation in the four pivotal phase III trials that have shown an improvement in overall survival in mccRCC first-line therapy, starting from 1 January 2017 to 1 June 2023. We highlight the different discontinuation scenarios and their influences on subsequent treatment options, aiming to provide more data to clinicians to navigate a complex decision-making process through a narrative review approach. We have identified several causes for discontinuations for patients treated with ICI-based combinations, such as interruption for drug-related adverse events, ICI treatment completion, treatment discontinuation due to complete response or maximum clinical benefit, or due to progression (pseudoprogression, systemic progression, and oligoprogression); for each case, an extensive analysis of the trials and current medical review has been conducted.

Verified
Journal Article
Open access
PDF file
Carmelo LafaceCarmelo Laface
Carmelo Laface
LSLuca Scartozzi
Luca Scartozzi
CPChiara Pisano
Chiara Pisano
PVPaola Vanella
Paola Vanella
AGAntonio Greco
Antonio Greco
GNGianmauro Numico
Gianmauro Numico
Background: Cabozantinib is a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor (VEGFR-TKI). These drugs are employed as therapy for several malignancies. In detail, Cabozantinib has demonstrated its efficacy against several malignancies. On the other hand, Cabozantinib and other VEGFR-TKIs can be responsible for various adverse events (AEs), in particular hepatic and dermatological AEs. Methods: To date, limited data are available in the literature regarding ocular AEs due to therapy with these drugs. In this regard, one case of corneal perforation during treatment with a VEGFR-TKI, Regorafenib, has been reported, while there are no data about Cabozantinib. In this paper, we present another clinical case of corneal perforation in a patient affected by advanced RCC and treated with Cabozantinib as a second-line therapy. The patient started Cabozantinib at the dosage of 60 mg/die although it was necessary to apply some dose reductions because of grade 2 AEs (according to CTCAE v6.0), such as asthenia, diarrhea, dysgeusia, and loss of appetite. Results: After approximately 15 months of treatment, the patient began to experience pain and vision loss in the right eye. A diagnosis of corneal perforation was made, followed by medical and surgical treatment. As regards the etiology of this pathology, all other possible causes were excluded, including a history of ocular disease, contact trauma, exposure to damaging agents (e.g., chemical agents and prolonged use of drugs such as topical NSAIDs), infections, or dry eye. Therefore, we hypothesized a correlation with Cabozantinib’s mechanisms of action and paused its administration. Conclusions: Cabozantinib may alter the ocular environment due to a lack of or imbalance in growth factors in the tear film, with a reduction in corneal epithelium proliferation. This condition might cause dry eye and a delay in corneal healing. Therefore, particular importance should be placed on ophthalmologic surveillance during treatment with these drugs in patients who develop ocular symptoms. Further in vitro and in vivo studies are necessary to deepen the knowledge about VEGFR-TKI-mediated ocular AEs.

8 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Carmelo LafaceCarmelo Laface
Carmelo Laface
LSLuca Scartozzi
Luca Scartozzi
CPChiara Pisano
Chiara Pisano
PVPaola Vanella
Paola Vanella
AGAntonio Greco
Antonio Greco
GNGianmauro Numico
Gianmauro Numico
Cabozantinib is a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor (VEGFR-TKI). These drugs are employed as therapy for several malignancies. In detail, Cabozantinib demonstrated its efficacy against Renal Cell Carcinoma, Hepatocellular carcinoma, and Medullary Thyroid Carcinoma. On the other hand, Cabozantinib can be responsible for various adverse events (AEs) that are common to the VEGFR-TKI family, in particular hepatic and dermatological AEs. In literature, few data have been divulged about ocular AEs due to therapy with these drugs. In this regard, only one case of corneal perforation during treatment with a VEGFR-TKI, Regorafenib, has been reported. In this paper, we present another clinical case of corneal perforation in a patient affected by advanced RCC and treated with Cabozantinib as second-line therapy. The patient started Cabozantinib at the dosage of 60 mg/die although it was necessary to apply some dose reductions because of grade 2 AEs (according to CTCAE v6.0) such as asthenia, diarrhea, dysgeusia, and loss of appetite. However, after approximately 15 months of treatment, the patient began to experience pain and vision loss in the right eye. Thus, the diagnosis of corneal perforation, medical and surgical treatment were performed as well as the interruption of Cabozantinib administration. VEGFR-TKIs’ mechanisms of action suggest a possible correlation with this AE. Therefore, particular importance should be given to ophthalmologic surveillance during treatment with these drugs, in any case of ocular symptoms.